This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

ZAVICEFTA® is indicated for the treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)1*

ZAVICEFTA is as effective as a carbapenem in hospitalised patients with aerobic Gram-negative HAP, including VAP2,3

REPROVE Phase III trial: 879 hospitalised adults with hospital-acquired pneumonia and ventilator-associated pneumonia.​​​​​​​

Patients with favourable clinical response at TOC (%)§​​​​​​​

Baseline pathogens: predominantly K. pneumoniae and P. aeruginosa including some ceftazidime-resistant strains. 100 patients (28%) had > 1 ceftazidime-resistant isolate.​​​​​​​

Explore more

REPRISE Phase III trial:

333 hospitalised adults with a cUTI or cIAI

View trial results

RECAPTURE Phase III trial:

1033 hospitalised adults with cUTI.

View trial results

RECLAIM Phase III trial:

1066 hospitalised adults with cIAI

View trial results


§Non-inferiority was concluded if the lower limit of the 95% CI was greater than –12.5%.2
cMITT population comprised patients with minimum disease criteria but excluded patients with only non-target pathogens.2 
​​​​​​​‡The clinically evaluable population comprised patients in the cMITT population who received an adequate course of treatment and had an assessable clinical outcome within the assessment window, no protocol deviations that could affect the assessment of efficacy, and no unacceptable previous or concomitant antibiotics.2
*Consideration should be given to official guidance on the appropriate use of antibacterial agents​​​​​​​

Abbreviations:

​​​​​​​AE, adverse event; CE, clinically evaluable; CI, confidence interval; cMITT, clinically modified intention-to-treat; HAP, hospital-acquired pneumonia; K. pneumoniae, Klebsiella pneumoniae; P. aeruginosa, Pseudomonas aeruginosa; TOC, test of cure; VAP, ventilator-associated pneumonia; cIAI, complicated intra-abdominal infection; E.coli, Escherichia coli; MITT, modified intention-to-treat; cUTI, complicated urinary tract infection.

References:
  1. ZAVICEFTA. Summary of Product Characteristics;
  2. Torres A, et al. Lancet Infect Dis 2018;18:285–95
  3. Torres A, et al. Open Forum Infect Dis 2019;6:ofz149 ​​​​​​​
PP-ZVA-GBR-1288. September 2021

1033 hospitalised adults with cUTI.

Learn more about the tolerability data of ZAVICEFTA from four Phase III clinical trials.

View safety profile

Professor Antoni Torres

Professor of Pulmonology and Respiratory Critical Care Medicine at University of Barcelona, Spain, talks about hospital-acquired pneumonia and ventilator-associated pneumonia, as well as the REPROVE study, a Phase III randomised clinical trial comparing ceftazidime-avibactam to meropenem.

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No